Literature DB >> 28279416

Cardio-oncology Related to Heart Failure: Epidermal Growth Factor Receptor Target-Based Therapy.

Benjamin Kenigsberg1, Varun Jain1, Ana Barac2.   

Abstract

Cancer therapy targeting the epidermal growth factor receptor (EGFR)/erythroblastic leukemia viral oncogene B (ErbB)/human EGFR receptor (HER) family of tyrosine kinases has been successfully used in treatment of several malignancies. The ErbB pathways play a role in the maintenance of cardiac homeostasis. This article summarizes current knowledge about EGFR/ErbB/HER receptor-targeted cancer therapeutics focusing on their cardiotoxicity profiles, molecular mechanisms, and implications in clinical cardio-oncology. The article discusses challenges in predicting, monitoring, and treating cardiac dysfunction and heart failure associated with ErbB-targeted cancer therapeutics and highlights opportunities for researchers and clinical investigators.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Cardiac therapies; Cardiovascular toxicity; EGFR signaling; HER2 pathways; Heart failure; Targeted cancer therapeutics

Mesh：

Substances：

Year:  2017        PMID： 28279416     DOI： 10.1016/j.hfc.2016.12.002

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN： 1551-7136            Impact factor:   3.179


  5 in total

Review 1.  Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies.

Authors:  Tolulope A Agunbiade; Raja Y Zaghlol; Ana Barac
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Oct-Dec

Review 2.  Cardio-oncology: Implications for Clinical Practice for Women.

Authors:  Seyed Ebrahim Kassaian; Bhumika Gandhi; Ana Barac
Journal:  Curr Cardiol Rep       Date:  2022-09-16       Impact factor: 3.955

3.  Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.

Authors:  Joerg Herrmann; Daniel Lenihan; Saro Armenian; Ana Barac; Anne Blaes; Daniela Cardinale; Joseph Carver; Susan Dent; Bonnie Ky; Alexander R Lyon; Teresa López-Fernández; Michael G Fradley; Sarju Ganatra; Giuseppe Curigliano; Joshua D Mitchell; Giorgio Minotti; Ninian N Lang; Jennifer E Liu; Tomas G Neilan; Anju Nohria; Rupal O'Quinn; Iskra Pusic; Charles Porter; Kerry L Reynolds; Kathryn J Ruddy; Paaladinesh Thavendiranathan; Peter Valent
Journal:  Eur Heart J       Date:  2022-01-31       Impact factor: 35.855

4.  Exploring Key Genes and Pathways of Cardiac Hypertrophy Based on Bioinformatics.

Authors:  Zhenzhen Zhang; Chunxiao Wang
Journal:  Dis Markers       Date:  2022-08-22       Impact factor: 3.464

Review 5.  Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity.

Authors:  Carmine Rocca; Ernestina Marianna De Francesco; Teresa Pasqua; Maria Concetta Granieri; Anna De Bartolo; Maria Eugenia Gallo Cantafio; Maria Grazia Muoio; Massimo Gentile; Antonino Neri; Tommaso Angelone; Giuseppe Viglietto; Nicola Amodio
Journal:  Biomedicines       Date:  2022-02-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.